Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 871 Präparate · 48256 Quellenpassagen · 124 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.5 · PDF-Seite 22
HOS-086328 · Präparat HOS-083284
Smoke cessation
Bupropion 150 100 q12h ↓ 22% ↓ 21%
150 600 q12h ↓ 66% ↓ 62%
Bupropion is primarily metabolised by CYP2B6. Concurrent administration of
bupropion with repeated doses of ritonavir is expected to decrease bupropion levels.
These effects are thought to represent induction of bupropion metabolism.
However, because ritonavir has also been shown to inhibit CYP2B6 in vitro, the
recommended dose of bupropion should not be exceeded. In contrast to long-term
administration of ritonavir, there was no significant interaction with bupropion after
short-term administration of low doses of ritonavir (200 mg twice daily for 2 days),
suggesting reductions in bupropion concentrations may have onset several days after
initiation of ritonavir co-administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 5df30991532aed9c4a46b92f3966cb44666a87fbb03fa46e4bc56a6eca98f939 · Zeichen 54774–56027 im Abschnitt
Wechselwirkungen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 55
HOS-086489 · Präparat HOS-083284
Smoke cessation
Bupropion 150 100 q12h ↓ 22% ↓ 21%
150 600 q12h ↓ 66% ↓ 62%
Bupropion is primarily metabolised by CYP2B6. Concurrent administration of bupropion
with repeated doses of ritonavir is expected to decrease bupropion levels. These effects
are thought to represent induction of bupropion metabolism. However, because ritonavir
has also been shown to inhibit CYP2B6 in vitro, the recommended dose of bupropion
should not be exceeded. In contrast to long-term administration of ritonavir, there was no
significant interaction with bupropion after short-term administration of low doses of
ritonavir (200 mg twice daily for 2 days), suggesting reductions in bupropion
concentrations may have onset several days after initiation of ritonavir co-administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage f83d8576f370ed4770b04d02e3ae3d60fb477b78c855c8f314d6b7bda88482c8 · Zeichen 57225–58475 im Abschnitt
Wechselwirkungen · DaTSCAN
DaTSCAN 74 MBq/ml solution for injection · Abschnitt 4.5 · PDF-Seite 5
HOS-090541 · Präparat HOS-084079
Ioflupane binds to the dopamine transporter. Medicines that bind to the dopamine transporter with high
affinity may therefore interfere with DaTSCAN diagnosis. These include amfetamine, bupropion,
cocaine, codeine, dexamfetamine, methylphenidate, modafinil, and phentermine. Selective serotonin
reuptake inhibitors (SSRIs), such as sertraline, may increase or decrease ioflupane binding to the
dopamine transporter. Serotonin-norepinephrine reuptake inhibitors (SNRIs), such as venlafaxine, may
decrease ioflupane binding to the dopamine transporter especially in patients on higher doses.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): codeine (HOS-090544) methylphenidate (HOS-090545) modafinil (HOS-090546) phentermine (HOS-087483) serotonin (HOS-085477) sertraline (HOS-086247) norepinephrine (HOS-090547) venlafaxine (HOS-086573) bupropion (HOS-086329) cocaine (HOS-090543) ioflupane (HOS-090542) dopamine (HOS-085948)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-25T02:00:00Z · SHA-256 f40f7ad424fba21e279058645a7f9123ad356bfb210f5e9a98e718256e3987ab · Passage b61bee0e5f8e9e99224bcb5a4db13e8cfb7d2e33ddbe5e161cf3103ca90bf479 · Zeichen 55–644 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 25–26
HOS-108940 · Präparat HOS-093083
Methadone Methadone: ↓ Monitoring plasma concentrations
of methadone is recommended.
Oral contraceptives
Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of
Kaletra with contraceptives
containing ethinyl oestradiol
(whatever the contraceptive
formulation e.g. oral or patch),
additional methods of
contraception must be used.
Smoking cessation aids
Bupropion Buproprion and its active If the co-administration of Kaletra
metabolite, hydroxybupropion: with bupropion is judged
AUC and Cmax ↓ ~50% unavoidable, this should be done
under close clinical monitoring for
This effect may be due to bupropion efficacy, without
induction of bupropion exceeding the recommended
metabolism. dosage, despite the observed
induction.
Thyroid hormone replacement therapy
Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone
reported indicating a potential (TSH) should be monitored in
interaction between ritonavir patients treated with levothyroxine
containing products and at least the first month after
levothyroxine. starting and/or ending
lopinavir/ritonavir treatment.
Vasodilating agents
25
Bosentan Lopinavir - ritonavir: Caution should be exercised in
Lopinavir/ritonavir plasma administering Kaletra with
concentrations may decrease due bosentan.
to CYP3A4 induction by When Kaletra is administered
bosentan. concomitantly with bosentan, the
efficacy of the HIV therapy should
Bosentan: be monitored and patients should
AUC: ↑ 5-fold be closely observed for bosentan
Cmax: ↑ 6-fold toxicity, especially during the first
Initially, bosentan Cmin: ↑ by week of co-administration.
approximately 48-fold.
Due to CYP3A4 inhibition by
lopinavir/ritonavir.
Riociguat Serum concentrations may be The co-administration of riociguat
increased due to CYP3A and with Kaletra is not recommended
P-gp inhibition by (see section 4.4 and refer to
lopinavir/ritonavir. riociguat SmPC).
Other medicinal products
Based on known metabolic profiles, clinically significant interactions are not expected between
Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bosentan (HOS-086291) riociguat (HOS-086293) dapsone (HOS-088141) trimethoprim (HOS-085184) sulfamethoxazole (HOS-084533) azithromycin (HOS-088112) fluconazole (HOS-087945) methadone (HOS-086198) bupropion (HOS-086329) levothyroxine (HOS-086339)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 8d752c4274572732732b0956ff6ff26c5cf23921c5ef2d225aedad5e185afa6d · Zeichen 59817–63890 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 60–61
HOS-109023 · Präparat HOS-093083
60
No clinical relevant interaction fluvastatin or pravastatin is
expected. recommended.
Pravastatin is not metabolised by
CYP450.
Fluvastatin is partially
metabolised by CYP2C9.
Opioids
Buprenorphine, 16 mg Buprenorphine: ↔ No dose adjustment necessary.
QD
Methadone Methadone: ↓ Monitoring plasma concentrations of
methadone is recommended.
Oral contraceptives
Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of
Kaletra with contraceptives
containing ethinyl oestradiol
(whatever the contraceptive
formulation e.g. oral or patch),
additional methods of contraception
must be used.
Smoking cessation aids
Bupropion Buproprion and its active If the co-administration of Kaletra
metabolite, hydroxybupropion: with bupropion is judged
AUC and Cmax ↓ ~50% unavoidable, this should be done
under close clinical monitoring for
This effect may be due to bupropion efficacy, without
induction of bupropion exceeding the recommended dosage,
metabolism. despite the observed induction.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluvastatin (HOS-086305) pravastatin (HOS-086306) buprenorphine (HOS-086193) methadone (HOS-086198) bupropion (HOS-086329)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 66795734d42d6453cc3ecae53ffe464f62e190070894ffc9d2f185474a98d737 · Zeichen 57035–59066 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 96–97
HOS-109102 · Präparat HOS-093083
96
Oral contraceptives
Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of
Kaletra with contraceptives
containing ethinyl oestradiol
(whatever the contraceptive
formulation e.g. oral or patch),
additional methods of contraception
must be used.
Smoking cessation aids
Bupropion Buproprion and its active If the co-administration of Kaletra
metabolite, hydroxybupropion: with bupropion is judged
AUC and Cmax ↓ ~50% unavoidable, this should be done
under close clinical monitoring for
This effect may be due to bupropion efficacy, without
induction of bupropion exceeding the recommended
metabolism. dosage, despite the observed
induction.
Thyroid hormone replacement therapy
Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone
reported indicating a potential (TSH) should be monitored in
interaction between ritonavir patients treated with levothyroxine
containing products and at least the first month after starting
levothyroxine. and/or ending lopinavir/ritonavir
treatment.
Vasodilating agents
Bosentan Lopinavir - ritonavir: Caution should be exercised in
Lopinavir/ritonavir plasma administering Kaletra with
concentrations may decrease due bosentan.
to CYP3A4 induction by When Kaletra is administered
bosentan. concomitantly with bosentan, the
efficacy of the HIV therapy should
Bosentan: be monitored and patients should be
AUC: ↑ 5-fold closely observed for bosentan
Cmax: ↑ 6-fold toxicity, especially during the first
Initially, bosentan Cmin: ↑ by week of coadministration.
approximately 48-fold.
Due to CYP3A4 inhibition by
lopinavir/ritonavir.
Riociguat Serum concentrations may be The co-administration of riociguat
increased due to CYP3A and with Kaletra is not recommended
P-gp inhibition by (see section 4.4 and refer to
lopinavir/ritonavir. riociguat SmPC).
Other medicinal products
Based on known metabolic profiles, clinically significant interactions are not expected between
Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) levothyroxine (HOS-086339) bosentan (HOS-086291) riociguat (HOS-086293) dapsone (HOS-088141) trimethoprim (HOS-085184) sulfamethoxazole (HOS-084533) azithromycin (HOS-088112) fluconazole (HOS-087945)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage eb717f7573e257a0db9660c2692fa6be3f81b8ac5b4c1043b1f49219b74ffa31 · Zeichen 58967–62731 im Abschnitt
Wechselwirkungen · Aptivus
Aptivus 250 mg soft capsules · Abschnitt 4.5 · PDF-Seite 22–23
HOS-114854 · Präparat HOS-094169
22
Bupropion 150 mg BID Bupropion Cmax ↓ 51% If the co-administration with
Bupropion AUC ↓ 56% bupropion is judged unavoidable,
this should be done under close
Tipranavir ↔ clinical monitoring for bupropion
efficacy, without exceeding the
The reduction of bupropion recommended dosage, despite the
plasma levels is likely due to observed induction.
induction of CYP2B6 and UGT
activity by RTV
Loperamide 16 mg QD Loperamide Cmax ↓ 61% A pharmacodynamic interaction
Loperamide AUC ↓ 51% study in healthy volunteers
demonstrated that administration
Mechanism unknown of loperamide and Aptivus, co-
administered with low dose
Tipranavir Cmax ↔ ritonavir, does not cause any
Tipranavir AUC ↔ clinically relevant change in the
Tipranavir Cmin ↓ 26% respiratory response to carbon
dioxide. The clinical relevance of
the reduced loperamide plasma
concentration is unknown.
Fluticasone propionate In a clinical study where ritonavir Concomitant administration of
Interaction study 100 mg capsules bid were co- Aptivus, co-administered with
performed only with administered with 50 µg low dose ritonavir, and these
ritonavir intranasal fluticasone propionate glucocorticoids is not
(4 times daily) for 7 days in recommended unless the
healthy subjects, the fluticasone potential benefit of treatment
propionate plasma levels outweighs the risk of systemic
increased significantly, whereas corticosteroid effects (see
the intrinsic cortisol levels section 4.4). A dose reduction of
decreased by approximately 86% the glucocorticoid should be
(90% confidence interval considered with close monitoring
82-89%). Greater effects may be of local and systemic effects or a
expected when fluticasone switch to a glucocorticoid, which
propionate is inhaled. Systemic is not a substrate for CYP3A4
corticosteroid effects including (e.g. beclomethasone). Moreover,
Cushing’s syndrome and adrenal in case of withdrawal of
suppression have been reported in glucocorticoids progressive dose
patients receiving ritonavir and reduction may have to be
inhaled or intranasally performed over a longer period.
administered fluticasone The effects of high fluticasone
propionate; this could also occur systemic exposure on ritonavir
with other corticosteroids plasma levels are as yet
metabolised via the P450 3A unknown.
pathway e.g. budesonide.
It is unknown whether the
combination of tipranavir with
ritonavir might cause a larger
increase in fluticasone exposure.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) loperamide (HOS-114855) ritonavir (HOS-084521) fluticasone propionate (HOS-086331) fluticasone (HOS-108914) propionate (HOS-108915) beclomethasone (HOS-086334) budesonide (HOS-086332)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-23T09:35:00Z · SHA-256 1c396190f98e89933229f2261b0e436bd43dac9c1de8e2dacaa36a755dc06dce · Passage 7522c1a17dc381755410649aa6db82293f9c200ad2f0eeed696045d4a966abe6 · Zeichen 60402–64824 im Abschnitt
Wechselwirkungen · Champix
CHAMPIX 0.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-115913 · Präparat HOS-094383
Bupropion
Varenicline did not alter the steady-state pharmacokinetics of bupropion.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-11T14:06:00Z · SHA-256 512fd3657f567938fdb59e3cf59c59c6c8e3323f46db8617dff61b0f88e2f1f0 · Passage 4ab4b8bca410b8ede1545a5340e8ad87c3c509c235a5591961abfcfca184ff59 · Zeichen 2251–2334 im Abschnitt
Wechselwirkungen · Champix
CHAMPIX 1 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 28
HOS-115943 · Präparat HOS-094383
Bupropion
Varenicline did not alter the steady-state pharmacokinetics of bupropion.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-11T14:06:00Z · SHA-256 512fd3657f567938fdb59e3cf59c59c6c8e3323f46db8617dff61b0f88e2f1f0 · Passage 4ab4b8bca410b8ede1545a5340e8ad87c3c509c235a5591961abfcfca184ff59 · Zeichen 2252–2335 im Abschnitt
Wechselwirkungen · Champix
CHAMPIX 0.5 mg film-coated tablets CHAMPIX 1 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 50
HOS-115972 · Präparat HOS-094383
Bupropion
Varenicline did not alter the steady-state pharmacokinetics of bupropion.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-11T14:06:00Z · SHA-256 512fd3657f567938fdb59e3cf59c59c6c8e3323f46db8617dff61b0f88e2f1f0 · Passage 4ab4b8bca410b8ede1545a5340e8ad87c3c509c235a5591961abfcfca184ff59 · Zeichen 2250–2333 im Abschnitt
Wechselwirkungen · Ranexa (previously Latixa)
Ranexa 375 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-118257 · Präparat HOS-094791
The potential for inhibition of CYP2B6 has not been evaluated. Caution is advised during
co-administration with CYP2B6 substrates (e.g. bupropion, efavirenz, cyclophosphamide).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) efavirenz (HOS-087947) cyclophosphamide (HOS-084539)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-11T13:07:00Z · SHA-256 0a3c1ac3a3e7045516969928ccd0918506379303d254770ac2a2d732c1bd1d40 · Passage 10a55e7638aa40a072e9e70fa9c50e10abefafb9097938a6339bc568f496d4bc · Zeichen 3389–3565 im Abschnitt
Wechselwirkungen · Ranexa (previously Latixa)
Ranexa 500 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 17
HOS-118304 · Präparat HOS-094791
The potential for inhibition of CYP2B6 has not been evaluated. Caution is advised during
co-administration with CYP2B6 substrates (e.g. bupropion, efavirenz, cyclophosphamide).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) efavirenz (HOS-087947) cyclophosphamide (HOS-084539)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-11T13:07:00Z · SHA-256 0a3c1ac3a3e7045516969928ccd0918506379303d254770ac2a2d732c1bd1d40 · Passage 10a55e7638aa40a072e9e70fa9c50e10abefafb9097938a6339bc568f496d4bc · Zeichen 3391–3567 im Abschnitt
Wechselwirkungen · Ranexa (previously Latixa)
Ranexa 750 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-118346 · Präparat HOS-094791
The potential for inhibition of CYP2B6 has not been evaluated. Caution is advised during
co-administration with CYP2B6 substrates (e.g. bupropion, efavirenz, cyclophosphamide).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) efavirenz (HOS-087947) cyclophosphamide (HOS-084539)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-11T13:07:00Z · SHA-256 0a3c1ac3a3e7045516969928ccd0918506379303d254770ac2a2d732c1bd1d40 · Passage 10a55e7638aa40a072e9e70fa9c50e10abefafb9097938a6339bc568f496d4bc · Zeichen 3390–3566 im Abschnitt
Wechselwirkungen · Efient
Efient 10 mg film-coated tablets. Efient 5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 6
HOS-120780 · Präparat HOS-095209
Medicinal products metabolised by CYP2B6:
Prasugrel is a weak inhibitor of CYP2B6. In healthy subjects, prasugrel decreased exposure to
hydroxybupropion, a CYP2B6-mediated metabolite of bupropion, by 23%. This effect is likely to be
of clinical concern only when prasugrel is co-administered with medicinal products for which
CYP2B6 is the only metabolic pathway and have a narrow therapeutic window
(e.g. cyclophosphamide, efavirenz).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): cyclophosphamide (HOS-084539) efavirenz (HOS-087947) bupropion (HOS-086329)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-22T14:15:00Z · SHA-256 bf0eaa99dea4480cd15ea241fb41ce985dc8e97851472df117f97dc0c795a95e · Passage fb8215c833ca7cbd9c31808c5ccc00ec508cce92747df1a4d5c640d188d8341f · Zeichen 4956–5391 im Abschnitt
Wechselwirkungen · Xalkori
XALKORI 200 mg hard capsules XALKORI 250 mg hard capsules XALKORI 20 mg granules in capsules for opening XALKORI 50 mg granules in capsules for opening XALKORI 150 mg granules in capsules for opening · Abschnitt 4.5 · PDF-Seite 15
HOS-126281 · Präparat HOS-096239
In vitro studies indicated that crizotinib is an inhibitor of CYP2B6. Therefore, crizotinib may have
the potential to increase plasma concentrations of coadministered medicinal products that are
metabolised by CYP2B6 (e.g., bupropion, efavirenz).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) efavirenz (HOS-087947)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-17T11:44:00Z · SHA-256 ef70dd9e8f617f709767e5bd4c7044eb23893a7ac40281434ebfa2fb8fb4e3d5 · Passage 5cd4c0cf68799c2f87087b0bea1c1edc60205e6a4e932a089f5ed8e9bc9f8b2c · Zeichen 4476–4722 im Abschnitt
Wechselwirkungen · Brintellix
Brintellix 5 mg film-coated tablets Brintellix 10 mg film-coated tablets Brintellix 15 mg film-coated tablets Brintellix 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-128728 · Präparat HOS-096615
Medicinal products lowering the seizure threshold
Antidepressants with serotonergic effect can lower the seizure threshold. Caution is advised when
concomitantly using other medicinal products capable of lowering the seizure threshold [e.g.,
antidepressants (tricyclics, SSRIs, SNRIs), neuroleptics (phenothiazines, thioxanthenes and
butyrophenones), mefloquine, bupropion, tramadol] (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): mefloquine (HOS-113850) bupropion (HOS-086329) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T08:59:00Z · SHA-256 39c9a9149ac76ca0fbe73df123a7c9f5de7dcd96ddbd144fa863659dff9cbf06 · Passage 4215f9337d32ce5f9513a0c375d72ab7bf582470185d4895b11be21a9349ab48 · Zeichen 2290–2692 im Abschnitt
Wechselwirkungen · Brintellix
Brintellix 5 mg film-coated tablets Brintellix 10 mg film-coated tablets Brintellix 15 mg film-coated tablets Brintellix 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-128731 · Präparat HOS-096615
6
CYP2D6 inhibitors
The exposure to vortioxetine increased 2.3-fold for area under the curve (AUC) when vortioxetine
10 mg/day was co-administered with bupropion (a strong CYP2D6 inhibitor 150 mg twice daily) for
14 days in healthy subjects. Co-administration resulted in a higher incidence of adverse reactions
when bupropion was added to vortioxetine than when vortioxetine was added to bupropion.
Depending on individual patient response, a lower dose of vortioxetine may be considered if strong
CYP2D6 inhibitor (e.g., bupropion, quinidine, fluoxetine, paroxetine) is added to vortioxetine
treatment (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): bupropion (HOS-086329) quinidine (HOS-085593) fluoxetine (HOS-085946) paroxetine (HOS-086246)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T08:59:00Z · SHA-256 39c9a9149ac76ca0fbe73df123a7c9f5de7dcd96ddbd144fa863659dff9cbf06 · Passage e7441a77ecd3d2a655c6c3420534f91fe90d1896c34a85c9057201186b2e49dc · Zeichen 2899–3522 im Abschnitt
Wechselwirkungen · Brintellix
Brintellix 5 mg film-coated tablets Brintellix 10 mg film-coated tablets Brintellix 15 mg film-coated tablets Brintellix 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-128746 · Präparat HOS-096615
Following multiple doses of vortioxetine, no inhibitory effect was observed in healthy subjects for the
cytochrome P450 isozymes CYP2C19 (omeprazole, diazepam), CYP3A4/5 (ethinyl estradiol,
midazolam), CYP2B6 (bupropion), CYP2C9 (tolbutamide, S-warfarin), CYP1A2 (caffeine) or
CYP2D6 (dextromethorphan).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): warfarin (HOS-085950) caffeine (HOS-085902) dextromethorphan (HOS-109265) omeprazole (HOS-085912) diazepam (HOS-085904) ethinyl estradiol (HOS-088135) midazolam (HOS-086167) bupropion (HOS-086329) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T08:59:00Z · SHA-256 39c9a9149ac76ca0fbe73df123a7c9f5de7dcd96ddbd144fa863659dff9cbf06 · Passage 1bd7041ffbd9c30da9604cfee35e7c1638e2123fda93208f7dba802a0877f2e6 · Zeichen 6952–7255 im Abschnitt
Wechselwirkungen · Brintellix
Brintellix 20 mg/ml oral drops, solution · Abschnitt 4.5 · PDF-Seite 25
HOS-128777 · Präparat HOS-096615
Medicinal products lowering the seizure threshold
Antidepressants with serotonergic effect can lower the seizure threshold. Caution is advised when
concomitantly using other medicinal products capable of lowering the seizure threshold [e.g.
antidepressants (tricyclics, SSRIs, SNRIs), neuroleptics (phenothiazines, thioxanthenes and
butyrophenones), mefloquine, bupropion, tramadol] (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): mefloquine (HOS-113850) bupropion (HOS-086329) tramadol (HOS-112871)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T08:59:00Z · SHA-256 39c9a9149ac76ca0fbe73df123a7c9f5de7dcd96ddbd144fa863659dff9cbf06 · Passage 4ed430f3a87ca89f996faf461be400c121e6bf5bba3177168988ee8fa21128d0 · Zeichen 2347–2748 im Abschnitt
Wechselwirkungen · Brintellix
Brintellix 20 mg/ml oral drops, solution · Abschnitt 4.5 · PDF-Seite 25
HOS-128779 · Präparat HOS-096615
CYP2D6 inhibitors
The exposure to vortioxetine increased 2.3-fold for area under the curve (AUC) when vortioxetine
10 mg/day was co-administered with bupropion (a strong CYP2D6 inhibitor 150 mg twice daily) for
14 days in healthy subjects. Co-administration resulted in a higher incidence of adverse reactions
when bupropion was added to vortioxetine than when vortioxetine was added to bupropion.
Depending on individual patient response, a lower dose of vortioxetine may be considered if a strong
CYP2D6 inhibitor (e.g., bupropion, quinidine, fluoxetine, paroxetine) is added to vortioxetine
treatment (see section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): paroxetine (HOS-086246) quinidine (HOS-085593) fluoxetine (HOS-085946) bupropion (HOS-086329)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T08:59:00Z · SHA-256 39c9a9149ac76ca0fbe73df123a7c9f5de7dcd96ddbd144fa863659dff9cbf06 · Passage 2244bfb8f15637b4fef22c953a2ed9f886a932e7777382293648f729a547497b · Zeichen 2903–3525 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.